EVALUATION OF PRO-APOPTOTIC EFFECTS OF β-MONOLINOLEIN ON METASTATIC BREAST CANCER CELL LINE MDA-MB-231 by SOFI, MOHAMMED SHAFI
Vol 12, Issue 3, 2019
Online - 2455-3891 
Print - 0974-2441
EVALUATION OF PRO-APOPTOTIC EFFECTS OF β-MONOLINOLEIN ON METASTATIC BREAST 
CANCER CELL LINE MDA-MB-231
MOHAMMED SHAFI SOFI*
Department of Microbiology and Biotechnology, Molecular Diagnostics and Nanobiotechnology Laboratories, Bangalore University, J.B. 
Campus, Bengaluru, Karnataka, India.Email: mshafi.sofii@gmail.com
Received: 06 October 2018, Revised and Accepted: 06 December 2018
ABSTRACT
Objectives: The objective of this study was to evaluate the β-monolinolein as a potential therapy for breast cancer treatment.
Methods: The cytotoxic activity of β-monolinolein was evaluated by 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and trypan 
blue exclusion assay. The cellular cytotoxicity and levels of cytosolic enzyme, lactate dehydrogenase (LDH), were measured by assessing μmoles of 
nicotinamide adenine dinucleotide/well/min. To confirm whether β-monolinolein induces apoptosis in 3,4-methylenedioxyamphetamine (MDA)-
MB-231 cells, western blot and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis were performed.
Results: For the 1st time, it was demonstrated that β-monolinolein strongly inhibits the growth of MDA-MB-231 cells, with an half maximal inhibitory 
concentration value of 12.5 µg/ml. <90% of cell death was achieved at higher concentrations after 48 h of treatment. Trypan blue assay showed 
that the cell viability was significantly decreased in a dose-dependent manner in MDA-MB-231 cells after 48 h of treatment. On the other hand, 
LDH activities in the cultured media were significantly elevated in a dose-dependent manner as compared to the control. Further, the western blot 
analysis showed that β-monolinolein leads to change in expression levels of important cell cycle regulators such as p21, Bax, Bcl-Xl, and Bcl-2 in 
MDA-MB-231 cells. The semiquantitative RT-PCR results indicated a significant upregulation of proapoptotic genes such as p53, p21, and Bax and 
downregulation of antiapoptotic gene Bcl-2.
Conclusion: These results indicate that β-monolinolein leads to change in expression of various cell cycle/apoptotic regulators and hence induces 
death in MDA-MB-231 cells.
Keywords: β-monolinolein, Cytotoxicity, Breast cancer treatment.
INTRODUCTION
Cancer is defined as a complex series of life-threatening disease 
condition and a leading cause of death caused by persistent tissue injury 
and host-environment interactions [1]. Worldwide, cancer is known to 
be the second leading cause of death and is responsible for an estimated 
9.6 million deaths in 2018. Globally, about one in six deaths are due 
to cancer [2]. The repeated exposure of carcinogens such as tobacco, 
ultraviolet light, and infections leads to various genetic (mutations), 
epigenetic (loss of heterozygosity), and global transcriptome changes 
(through inflammation pathways) and is associated with increased 
cancer risk [3]. Among cancers, breast cancer is projected to be among 
the most common cancer and is the most frequent malignant neoplasm 
in women [4]. Due to increased occurrence of cancer and worldwide 
prevalence during the past decade, it has posed a great challenge to 
the health-care professionals. The latest WHO statistics suggests about 
45% increase in the global cancer deaths by 2030, of which 70% would 
be contributed from developing countries like India [5]. Despite a better 
understanding of disease and the advent of modern technology and 
rationally targeted drugs, the incidence and cure rate of cancer have not 
improved. Cancer cure and prevention, therefore, remain a high priority 
for scientific community across the world [6].
Although a range of conventional therapies based on chemotherapy, 
surgery, and radiotherapy is available, these approaches are in many 
cases of limited efficacy [7]. Moreover, the current anticancer regimens 
are frequently associated with significant levels of toxicity and the 
emergence of drug resistance. One major challenge to relieve cancer 
burden is to develop highly effective drugs with specificity on cancers 
but little or no side effects on normal mammalian cells [8]. Many research 
projects have been focused on developing new chemotherapies either 
by exploring the anticancer ability of novel compounds or by assessing 
drugs conventionally used in other clinical diseases. Hence, the search 
for cancer treatment continues to be a worldwide effort. As part of 
this effort, various natural products, especially from medicinal plants, 
have been tested against various cancer cell lines [9,10]. Still, there 
has been a long-standing interest in the identification of medicinal 
plants and derived natural products for developing novel cancer 
therapeutics [11,12]. Natural products have been playing a major 
role in the search for novel drugs for numerous illnesses including 
cancer [13,14]. Throughout human history and especially in the past 
century, natural products have virtually remained undisputed leaders 
among the various therapeutic tools humans have employed against 
many diseases including cancer [15]. Natural products have been 
found to be a relevant source of novel and potent bioactive compounds 
with minimal side effects in vivo. Many phytocompounds used for the 
treatment of malignant tumors are cytotoxic drugs that can induce tumor 
cell death by apoptosis [16]. Chemotherapy with cytotoxic drugs is the 
main treatment modality for certain types of cancer [17]. In vitro cell-
based assays have been developed to rapidly determine the cytotoxic 
activity of several compounds. Cell-based assays are also useful in 
identifying variations in susceptibility of different target cells to several 
chemotherapeutic agents [18,19]. The specific intracellular damage 
induced by these drugs is generally well characterized. For example, 
cisplatin, one of the most widely used anticancer drugs, reacts with the 
target genomic DNA to form DNA adducts [20]. This DNA damage can 
induce cell cycle arrest and apoptosis [21,22]. Inhibition of proliferation 
and/or induction of apoptosis in cancer cells are the most important 
characteristic of many anticancer agents [23]. However, the mechanisms 
by which the specific damage induced by the chemotherapeutic agents 
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that are converted into a death signal remain poorly understood. Breast 
cancer has been found attenuated by an appreciable amount of natural 
substances including phytochemicals and dietary substances which 
affect cell proliferation, cell differentiation, angiogenesis, apoptosis, 
and a few other cellular transduction pathways [24]. The increasing 
global incidence of breast cancer emphasizes the need to understand 
the mechanism involved in breast tumorigenesis and to identify 
novel, safe, and efficient anticancer drugs for the treatment of breast 
cancer. Nevertheless, the continued search for safer and more effective 
natural agents to improve the efficiency of breast cancer treatment is 
furthermore a need [25].
Despite the reports on the biological activities of these essential oils, data 
on their cytotoxicity are still scarce in the literature [26,27]. Discovery 
and development of new chemopreventive drugs against breast cancer 
with an interesting safety and efficacy to improve breast cancer 
management and reduce the high cost and pain of patients are an urgent 
necessity [28]. Hence, the objective of the present study is to evaluate 
the cytotoxic and proapoptotic activity and potency of β-monolinolein 




β-monolinolein (9,12-octadecadienoic acid (Z, Z)-, 2-hydroxy-1-
(hydroxymethyl) ethyl ester) was isolated, identified, and characterized 
from the leaves of Abrus precatorius L. using various techniques such as 
Soxhlet extraction, thin-layer chromatography, column chromatography, 
high-performance liquid chromatography (HPLC), nuclear magnetic 
resonance spectroscopy (NMR), and by gas chromatography–mass 
spectrum analysis, as discussed in our published research work [29].
Cell culture and maintenance
MDA-MB-231 cells were maintained in Dulbecco’s Modified Eagle’s 
medium with 10% fetal bovine serum, 100 U/ml penicillin, and 
100 μg/ml streptomycin in a humidified atmosphere of 95% air and 
5% CO2 at 37°C.
(3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay for cytotoxicity
Analysis of cell viability was done by standard colorimetric MTT 
assay. After 24 h, cells were treated with different concentrations of 
β-monolinolein for 48 h. 20 μl of MTT (5 mg/ml) reagent was added 
to each well and then incubated for 3 h at 37°C in CO2 incubator [18]. 
After 3 h, the medium was removed and 200 μl of dimethyl sulfoxide 
(DMSO) was added and mixed. Absorbance was recorded at 595 nm 
with multiwell-plate reader. The percentage of cell viability of 
β-monolinolein was calculated according to the following equation: 
Percentage of cell viability=(OD of treated cells/OD of control cells) 
×100. The concentration of drug that inhibits 50% of the cells (half 
maximal inhibitory concentration [IC50] values) for these samples was 
obtained from dose-response curves [30].
Trypan blue dye exclusion assay
For the determination of cell viability, MDA-MB-231 breast cancer cells 
were plated at a density of 1×106 cells/well in 24-well tissue culture 
plates and cultured for 48 h at 37°C. The medium was replaced with 
serum-free medium and cells were treated with various concentrations 
of β-monolinolein (10, 20, 30, 40, and 50 μg/ml) for a further 48 h. The 
cultures were harvested and washed twice with phosphate-buffered 
saline (PBS), cell pellet was then suspended with 0.5 ml PBS. Then, 
20 μl of cell was mixed with equal volume of 0.4% trypan blue (Sigma-
Aldrich, USA). The number of live/dead cells was directly counted on 
hemocytometer under microscope. The percentage viability for the 
cells was calculated as (live cells/total cells) ×100.
Lactate dehydrogenase (LDH) cytotoxicity assay
MDA-MB-231 cells (1×106 cells/well) were plated in 100 µl of medium 
per well in 96-well plates and were allowed to attach to the plate for 
24 h. After cell attachment (24 h), cells were treated with increasing 
concentrations of β-monolinolein (10, 20, 30, 40, and 50 μg/ml) 
for a further 48 h. The extracellular LDH activity was measured in 
the medium after 24 h. Following treatment, culture supernatants 
were then collected from each well and transferred to individual 
tubes containing Tris-ethylenediaminetetraacetic acid-nicotinamide 
adenine dinucleotide (NADH) buffer followed by 10 min incubation at 
37°C and the addition of pyruvate solution. Absorbance was read at 
339 nm using an ultraviolet (UV)-visible spectrophotometer (UV-260, 
Shimadzu Corp, Japan). LDH activity was expressed as µmoles of NADH 
used per minute per well. All experiments were repeated 3 times in 
triplicates.
Western blot analysis
Change in the protein levels of various cell cycles/apoptotic regulators 
such as p21, BAX, Bcl-Xl, and BCl-2 was analyzed by western blot 
analysis. Specific antibodies to p21, BAX, Bcl-Xl, BCl-2, and β-actin 
(loading control) were used. The membranes were washed with Tris-
Buffered Saline Tween-20 and incubated with specific secondary 
antibodies. Femtolucent substrate (G-biosciences, USA) was used to 
detect the antibodies by exposing the blot to an X-ray film. Developer 
and fixer were purchased from Eastman Kodak (USA).
Gene expression analysis by semiquantitative reverse transcription-
polymerase chain reaction (RT-PCR)
Expression level of various apoptosis-related genes was analyzed 
by semiquantitative RT-PCR. For expression analysis, gene-specific 
primers were used as listed in Table 1.
Statistical analysis
The data represent the mean ± standard deviation of three independent 
experiments each in a triplicate. The significance between control and 
treated groups was analyzed by Student’s t-test and p<0.05 was taken 
as statistically significant by GraphPad Prism 5.0 Software (GraphPad 
Software Inc., CA, USA).
RESULTS
MTT assay for cytotoxicity
Treatment of MDA-MB-231 cells for 48 h with β-monolinolein showed 
a very significant and higher cytotoxic activity with an IC50 value of 
12.5 µg/ml (Fig. 1). These results indicated that β-monolinolein has a 
potent cytotoxic activity on MDA-MB-231 breast cancer cells.
Morphological studies
Microscopic examination of MDA-MB-231 cells treated with 
β-monolinolein showed significant morphological changes such as 
shrinkage and detachment from the surface (Fig. 2). Due to the loss of 
cells, differences in the cell number can also be visualized in culture 
dish when it was treated with β-monolinolein for 48 h in comparison to 
the control dish. These results show that β-monolinolein has a potent 
cytotoxic activity on breast cancer cells.
Table 1: Amplicon size and sequence of the primers used in 
semiquantitative RT-PCR
Sl. No Gene Amplicon size Primer sequence
1. p21 147 bp Forward: GCCATTAGCGCATCACAGT
Reverse: TGCGTTCACAGGTGTTTCTG
2. BID 133 bp Forward: TTGTGATGCACTCATCCCTG
Reverse: CCATAAGGAGGAAGCGGGTA
3. BAX 132 bp Forward: CTCAGCCCATCTTCTTCCAG
Reverse: GCTGGATCCAAGACCAGG 
4. Bcl-2 141 bp Forward: CCAGAGGAGGAGGTAGGGAC
Reverse: TGATGTGAGTCTGGGCTGAG
5. Rpl35a 141 bp Forward: CTGGTTTTGTTTGGTTTGCC
Reverse: AAGGGAGCACACAGCTCTTC
RT-PCR: Reverse transcription-polymerase chain reaction
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Trypan blue dye exclusion assay
Direct counting for non-viable and viable cells using trypan blue 
exclusion test showed that β-monolinolein treated cells with the different 
concentrations ranging from 10 to 50 µg/ml for 48 h reduced the cell 
viability in dose-dependent manner (Fig. 3). At 10 µg/ml viability was 
decreased to 62.41%, whereas at 50 µg/ml viability reached to minimum 
value of 11.84%. This assay showed that β-monolinolein killed human 
breast cancer cells at a higher rate than control (without DMSO) and 
DMSO. The data suggest that β-monolinolein treatment results in dose-
dependent growth inhibition and induces cell death in MDA-MB-231cells.
LDH cytotoxicity assay
LDH level was increased from 1.0 µmoles (control) to 8.83 µmoles (treated 
at 50 µg/ml of extract) of NADH. Cells treated with β-monolinolein for 
48 h resulted in a significant increase (7.83-fold) in LDH release relative 
to the untreated cells in dose-dependent manner (Fig. 4). Cytotoxic 
effects of β-monolinolein due to membrane damage leads to cytosolic 
LDH release could be one of the reasons, leading to cell death.
Western blot analysis
Western blot analysis shows that β-monolinolein treatment leads 
to upregulation of proapoptotic proteins such as p21 and Bax. 
Downregulation of antiapoptotic proteins Bcl-Xl and Bcl-2 in MDA-
MB-231 cells was also determined after treatment with β-monolinolein 
(Fig. 5a). As shown in Fig. 5b, the treatment leads to a 9-fold upregulation 
of p21, 3-fold upregulation of Bax, 5-fold downregulation of Bcl-Xl, 
and 6–7-fold downregulation of Bcl-2 at 20 μg/ml concentration of 
β-monolinolein. Together these results show that β-monolinolein has 
a potent effect on expression of various regulators of the cell cycle and 
apoptosis.
Gene expression analysis by semiquantitative RT-PCR
Semiquantitative RT-PCR analysis indicates a significant upregulation 
of proapoptotic genes such as p21, BID, and Bax on treatment with 
Fig. 1: Cytotoxic activity of β-monolinolein on 
3,4-methylenedioxyamphetamine (MDA)-MB-231 cells. 
β-monolinolein showed significant cytotoxic activity at 
concentration of 5–50 µg/ml after 48 h of treatment. Dose-
dependent cytotoxic activity of β-monolinolein on MDA-MB-231 cells 
was observed, with an half maximal inhibitory concentration value 
of 12.5 µg/ml. Values are mean ± standard error mean of at least 
three independent experiments, each in triplicates
Fig. 3. Effect of β-monolinolein on cell viability of 
3,4-methylenedioxyamphetamine-MB-231 cells by trypan blue 
assay. Viability reached a minimum value of 11.84% (at 50 µg/ml) 
in treated cells. Data are representative of three independent 
experiments with three replicates. Error bars represent mean ± 
standard deviation
Fig. 4: Lactate dehydrogenase activity in control and β-monolinolein 
treated 3,4-methylenedioxyamphetamine-MB-231 cells. Lactate 
dehydrogenase level was increased from 1.0 µmoles (control) 
to 8.83 µmoles of NADH in treated cells with 50 µg/ml. Data are 
representative of three independent experiments with three 
replicates. Error bars represent mean ± standard deviation
Fig. 2: Microscopic view of human breast cancer 
3,4-methylenedioxyamphetamine-MB-231 cells 
(×10 magnification), (a) non-treated control cells at 0 h 
and (b) 48 h; (c) β-monolinolein treated cells at 0 h and (d) 48 h 
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β-monolinolein. In addition, downregulation of antiapoptotic gene 
Bcl-2 was also observed (Fig. 6a). The graphical representation of the 
quantitative analysis of RT-PCR results was shown in Fig. 6b. Treatment 
of MDA-MB-231 cells with β-monolinolein leads to approximately 
8–9-fold upregulation of p21, 5-fold upregulation of BID, and 3–4-fold 
upregulation of BAX. In the same way, around 4–5-fold downregulation 
of antiapoptotic gene Bcl-2 was quantified after treatment with 
β-monolinolein at concentration of 20 μg/ml. These results indicate 
that β-monolinolein leads to change in expression of various cell cycle/
apoptotic regulators and hence induces death in MDA-MB-231 cells.
DISCUSSION
Medicinal herbs have been widely accepted with escalating awareness 
all over the world. Nowadays, about 65% of plant-based medicines 
are used for cancer therapy [31]. Clinically used anticancer drugs 
generally induce complex responses in cancer cells [32]. Studying 
the mechanisms underlying these responses is important to 
understand how drugs should be optimally used and why tumor cells 
become resistant to them. Various forms of cancers require multiple 
approaches for their treatment, which opens a wide field of research 
in the discovery of new anticancer natural products [33]. Hence, it is 
important to study novel mechanisms of selected cytotoxic compounds 
action that could potentially represent new weapons in the fight against 
cancer [34]. Therefore, the continued research in this field appears to 
hold great promise for newer therapeutic molecules to treat cancer. 
Medicinal plants are the richest bioresource of drugs in traditional 
medicine, pharmaceutical intermediates, and chemical entities for 
synthetic drugs [35]. Medicinal plant extracts usually contain many 
secondary metabolites with varying bioactivities [36]. Several bioactive 
compounds have been discovered in plants and used directly as patented 
drugs such as taxol, artemisinin, and maprouneacin [37]. Cytotoxicity 
screening models provide important preliminary data to select plant 
extracts with potential anticancer properties [38]. In our published 
research work, it was found that the leaf extract of Abrus precatorius 
is known to consist of cytotoxic compounds that are very effective 
against metastatic breast cancer MDA-MB-231 cells [39]. Further, two 
anticancer compounds β-monolinolein and stigmasterol hemihydrate 
were isolated from the leaves of A. precatorius by various bioassay-
guided isolation and characterization techniques [29]. Both these 
compounds were experimentally proved to be having chemopreventive 
Fig. 5: Western blot analysis showing change in 
expression of various apoptotic and cell cycle regulators 
in 3,4-methylenedioxyamphetamine-MB-231 cells. 
(a) Lane 1=Untreated; Lane 2–4=Cells treated with indicated 
concentrations of β-monolinolein, after 48 h of treatment. 
(b) Graphs show the densitometry quantitation of the proteins 
indicated in the western blots
a
b
Fig. 6: Semiquantitative reverse transcription-polymerase 
chain reaction (RT-PCR) analysis of various cell cycle regulators, 
(a) Lane 1 and 2 =Untreated; Lane 3–8=Cells treated with indicated 
concentrations of β-monolinolein, (b) The graphs represent the 
change in expression of the indicated genes as quantitated by 
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and antibreast cancer activity both in vitro and in vivo experimental 
models. Now, in the present study, β-monolinolein that was having 
maximum cytotoxic activity was tested separately for its cytotoxic and 
proapoptotic activity and for molecular mechanism behind its activity 
on metastatic breast cancer cell line MDA-MB-231.
The β-monolinolein is long-chain unsaturated fatty acids. It was previously 
reported that fatty acid esters are known to exhibit cytotoxicity against 
HeLa, HepG2, and MCF-7 cells [40,41]. In the present investigation, for 
the 1st time, it was demonstrated that β-monolinolein was found to be 
significantly active and inhibits growth of MDA-MB-231 cells, with an 
IC50 value of 12.5 μg/ml. More than 90% of cell death was achieved at 
higher concentrations after 48 h of treatment. Microscopic examination 
of MDA-MB-231 cells treated with β-monolinolein showed significant 
morphological changes such as shrinkage and detachment from the 
surface. Due to the loss of cells, differences in the cell number can also 
be visualized in culture dish when it was treated with β-monolinolein 
for 48 h in comparison to the control dish. These results show that 
β-monolinolein has a potent cytotoxic activity on breast cancer cells.
Further, trypan blue exclusion assay showed the reduction of cell viability 
in concentration-dependent manner in treated MDA-MB-231 cells 
as compared to the control cells. Another parameter for cell death 
is the integrity of the cell membrane which can be measured by 
the cytoplasmic enzyme released by damaged cells. LDH is a stable 
cytoplasmic enzyme abundant in the cytosol of all mammalian cells. It 
is rapidly released into the cell culture supernatant on damage of the 
plasma membrane [42]. The cytotoxicity induced by β-monolinolein 
was assessed by LDH leakage into the culture medium. Cell membrane 
rupture was defined as the ratio of LDH activity in the supernatant of 
treated cells to LDH activity released in the control cells. The released 
LDH levels were significantly elevated after 48 h of β-monolinolein 
treatment in the medium in comparison to the non-treated cells.
The western blot results showed that β-monolinolein leads to 
upregulation of p21 and Bax proteins in a concentration-dependent 
manner and downregulation of Bcl-Xl and Bcl-2 in treated cells. 
Collectively the results proved that β-monolinolein has a very 
prominent effect on the expression levels of critical regulators 
of the cell cycle and apoptosis. Several studies have shown that 
phytochemicals such as curcumin, resveratrol, flavopiridol, indole-
3-carbinol, evodiamine, and green tea polyphenols are also known to 
induce apoptosis by downregulating expression of Bcl-2 and Bcl-XL in 
several cancer cell lines [43]. Cell cycle progression is controlled by the 
expression of various genes [44]. The balance between the expression 
of proapoptotic and antiapoptotic genes is important to determine 
whether cell would survive or die. Various unfavorable conditions 
alter the steady-state levels of these genes resulting in programmed 
cell death [45]. The increase in the expression of apoptotic genes leads 
to the release of cytochrome C from the mitochondria, which triggers 
activation of caspases that, in turn, lead to apoptosis of the cells [46]. 
The results showed that the treatment of MDA-MB-231 cells with the 
β-monolinolein regulates the expression of key cell cycle mediators in 
MDA-MB-231 cells. RT-PCR results indicated a significant upregulation 
of proapoptotic genes such as p53, p21, and Bax and downregulation of 
antiapoptotic gene Bcl-2. These genes have also been demonstrated to 
play an important role in initiation and execution of apoptosis in tumors 
exposed to radiation or chemotherapy. The Bcl-2 family proteins are 
well known to be decisive regulators in promoting cell death [47].
CONCLUSION
Our findings suggest that β-monolinolein might prove to be a potential 
source of anticancer lead molecule. However, further, molecular work 
is still needed to validate β-monolinolein for possible anticancer drug 
development and the clinical purpose.
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